Physician profile
Sara Catrett
NPI 1154830388
$3,353.26
in general payments reported to CMS, 2019-2025
28 companies · $903 in 2025
The $903 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $440 · 2023: $885 · 2024: $662 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $406.60 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $347.99 | 2022-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $347.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $280.35 | 2021-2025 | Lokelma, Farxiga, Andexxa |
| Amgen INC. | $252.58 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.31 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $169.47 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $167.85 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.89 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $147.23 | 2021-2025 | Watchman Access System |
| Atricure, INC. | $125.82 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.10 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $106.39 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $69.80 | 2021-2023 | Xarelto |
| Abbott Laboratories | $67.87 | 2022-2024 | Mitraclip, Jot Dx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $53.95 | 2021-2023 | Nexletol |
| Cvrx, INC. | $49.25 | 2024 | Barostim Neo System |
| Baxter Healthcare | $41.04 | 2024 | Hillrom - Eli280 Cardiograph |
| Lexicon Pharmaceuticals, INC. | $35.48 | 2023 | Inpefa |
| Genzyme Corporation | $33.78 | 2024 | |
| Alnylam Pharmaceuticals INC. | $31.38 | 2021-2023 | Onpattro |
| Lemaitre Vascular, INC. | $28.26 | 2022 | |
| Vital Connect, INC | $27.22 | 2024 | Vitalpatch Rtm |
| Lantheus Medical Imaging, INC. | $20.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.93 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $15.56 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $15.39 | 2024 | |
| Irhythm Technologies, INC. | $14.63 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Catrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.